Bio-Techne (TECH) Current Deferred Revenue (2014 - 2026)
Bio-Techne (TECH) posted quarterly Current Deferred Revenue of $40.7 million for Q1 2026, up 26.13% year-over-year from $32.3 million in Q1 2025, and up 31.16% quarter-over-quarter from $31.0 million in Q4 2025.
Bio-Techne (TECH) Current Deferred Revenue (2014 - 2026) Analysis & Trends
Bio-Techne's Current Deferred Revenue history runs 13 years deep, the most recent figure standing at $40.7 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 26.13% year-over-year to $40.7 million; the TTM figure through Mar 2026 stood at $40.7 million (up 26.13% YoY), while the FY2025 annual figure was $32.6 million, up 7.85% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $40.7 million, up from $31.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $40.7 million in Q1 2026, with the low at $21.8 million in Q4 2022.
- The 5-year median for Current Deferred Revenue is $30.1 million (2023), against an average of $28.5 million.
- Peak annual rise in Current Deferred Revenue reached 38.0% in 2023, while the deepest fall reached 3.53% in 2023.
- Bio-Techne's Current Deferred Revenue stood at $21.8 million in 2022, then surged by 38.0% to $30.1 million in 2023, then grew by 1.0% to $30.4 million in 2024, then grew by 2.07% to $31.0 million in 2025, then soared by 31.16% to $40.7 million in 2026.
- Business Quant data shows TECH's Current Deferred Revenue at $40.7 million in Q1 2026, $31.0 million in Q4 2025, and $30.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.70 Mn |
| Dec 31, 2025 | 31.03 Mn |
| Sep 30, 2025 | 30.45 Mn |
| Jun 30, 2025 | 32.57 Mn |
| Mar 31, 2025 | 32.27 Mn |
| Dec 31, 2024 | 30.40 Mn |
| Sep 30, 2024 | 29.20 Mn |
| Jun 30, 2024 | 30.20 Mn |
| Mar 31, 2024 | 30.11 Mn |
| Dec 31, 2023 | 30.10 Mn |
| Sep 30, 2023 | 25.80 Mn |
| Jun 30, 2023 | 24.60 Mn |
| Mar 31, 2023 | 24.88 Mn |
| Dec 31, 2022 | 21.81 Mn |
| Sep 30, 2022 | 22.06 Mn |
| Jun 30, 2022 | 25.50 Mn |
| Mar 31, 2022 | 23.11 Mn |
| Dec 31, 2021 | 19.08 Mn |
| Sep 30, 2021 | 20.10 Mn |
| Jun 30, 2021 | 20.00 Mn |